Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Do not inject the medication
You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk
Your Content Goes Here Pancreatic glucagon release Glucose-dependent insulin secretion Discover More GLP-1 acts as an incretin that enhances insulin release from pancreatic beta-cells only when blood glucose is elevated, thereby reducing the risk of hypoglycemia
Will my insurance cover peptide therapy
The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks
En 2025 se replic este efecto y se describi una va ALT en lneas cancerosas (PMID 40908429)
US$ 24.14
US$ 29.61
US$ 26.95
US$ 19.99
US$ 27.00
US$ 25.75
US$ 21.97
US$ 26.48
